Teva Pharmaceutical Industries Limited (TEVA)’s share was trading at $13.94 as of April 7th. TEVA’s trailing and forward P/E were 872 and 5.37 respectively according to Yahoo Finance. After ...

We will work closely with Teva to ensure access of this medicine for payers, healthcare professionals and patients in the U.S.,” she added.

Teva Pharmaceutical (NYSE:TEVA) and South Korean generic drugmaker Samsung Bioepis announced Monday the U.S. commercial availability of Epysqli, a biosimilar drug targeting AstraZeneca’s (NASDAQ ...

Teva and Samsung Bioepis are offering Epysqli, which is is a biosimilar to Alexion Pharmaceuticals' Soliris (eculizumab) for the treatment of paroxysmal nocturnal hemoglobinuria, atypical ...

Soliris® (eculizumab), making it one of the greatest cost-saving biosimilars to Soliris® in the U.S. Teva and Samsung Bioepis entered into a strategic partnership in January 2025 for the ...

Get your feet ready, it’s almost sandal season and if you haven’t filled your closet with at least one new pair, these Nordstrom Rack sandal deals are just for you. Here’s a look at some of ...

Teva and Celltrion’s attempt to muscle in on the multi-billion dollar US cancer and inflammatory disease drug market has hit a setback after the FDA rejected two key biosimilars because of ...

The management of Israeli pharma group Teva has laid out its strategy for a return to growth after a challenging few years, with a greater emphasis on innovative medicines and a focus on complex ...

Norwich argued that if upheld, FDA’s determination will prohibit Norwich from marketing those products until at least June 29, 2028, assuming Teva launches its rifaximin product in January 2028.

Norwich had asked the District Court for a judgment declaring the FDA's decision to issue tentative approval for Norwich's Abbreviated New Drug Application (ANDA) for XIFAXAN ® (rifaximin) 550 mg and ...